Influenza vaccine 2006-2007

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1245, 2006, Pages 81-83

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; THIOMERSAL; TRIPLE VACCINE;

ASTHMA; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; GUILLAIN BARRE SYNDROME; HUMAN; HYPERSENSITIVITY; INFLUENZA; INJECTION SITE REACTION; NOSE CONGESTION; RHINORRHEA; SHORT SURVEY; SINGLE DRUG DOSE; SORE THROAT; VIRUS TRANSMISSION; ARTICLE; DISEASE TRANSMISSION; IMMUNOLOGY; TIME; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TIME FACTORS; VACCINATION;

EID: 39049190921     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55 (RR 10):1.
2. M Bigham and R Copes. Thimerosal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf 2005; 28:89.
3. KG Nicholson et al. Influenza. Lancet 2003; 362:1733.
4. T Jefferson et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165.
5. T Jefferson et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: a systematic review. Lancet 2005; 365:773.
6. MJ Gaglani et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004; 158:65.
7. RB Belshe et al. Safety, efficacy and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004; 39:920.
8. P Haber et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004; 292:2478.
9. HS Izurieta et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005; 294:2720.
10. TR Talbot et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemol 2005; 26:494.
11. T Vesikari et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590.
12. J Lin et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991.